Nuvation Bio Inc Ordinary Shares - Class A NUVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
-
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
-
Nuvation Bio to Participate in Upcoming Investor Conferences
-
Nuvation Bio Granted FDA Fast-Track Designation for Glioma Treatment
-
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
-
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Trading Information
- Previous Close Price
- $4.55
- Day Range
- $4.37–4.52
- 52-Week Range
- $3.93–9.75
- Bid/Ask
- $4.44 / $4.45
- Shares Outstanding
- 351.12M
- Market Cap
- $1.57B
- Volume/Avg
- 413,885 / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 305
- Website
- https://www.nuvationbio.com
Valuation
|
Metric
|
NUVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.27 |
Price/Sales | 9.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NUVB
|
|---|---|
Quick Ratio | 7.98 |
Current Ratio | 8.37 |
Interest Coverage | −5.41 |
Quick Ratio
NUVB
Profitability
|
Metric
|
NUVB
|
|---|---|
Return on Assets (Normalized) | −16.94% |
Return on Equity (Normalized) | −34.33% |
Return on Invested Capital (Normalized) | −24.93% |
Return on Assets
NUVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|cbdk$!C | LOCK|x^@$ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|T@D%H^Q | LOCK|#jK# | $84B | |||
| Moderna Inc
MRNA
| LOCK|y%?$j>C | LOCK|>P? | $83B | |||
| argenx SE ADR
ARGX
| LOCK|K^Dwgw | LOCK|k<g | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%$XLFYT | LOCK|wv | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|mTbJ>Q | LOCK|!?ty | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%ZR>!?G | LOCK|RHr<c | $29B | |||
| Incyte Corp
INCY
| LOCK|qK>&Xhm | LOCK|Y>g | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|!b#&&F | LOCK|$L | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|YG!xg# | LOCK|hX< | $14B |
United States